Announcement on Resolutions of the 5th Session of the 10th Board of Directors
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2018-022
Bond Abbreviation: 13 Jianfeng 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
10th Board of Directors Resolution Announcement
The board of directors and all directors of the company guarantee that the content of this announcement does not contain any False records, misleading statements or major omissions, and bear individual and joint responsibility for the authenticity, accuracy and completeness of its contents .
1. Board Meeting
(I) The convening and convening of this board meeting complies with relevant laws, regulations and the company's "Articles of Association.
(II) of July 31, 2018, the company issued the notice of the board meeting by fax, email and personal delivery.
(III) August 3, 2018, this board meeting will be held by means of communication vote.
(IV) company has nine directors and nine directors who participated in the voting.
2. Board Meeting Deliberations
(I) Passed the "Proposal on Capital Increase of Shanghai Beika by Subsidiary Jianfeng Pharmaceutical".
After deliberation and voting, the Board of Directors passed the "Proposal on the Capital Increase of Shanghai North Card by Subsidiary Peak Pharmaceutical".
Voting result: 9 votes in favor, 0 votes against, 0 abstentions.
For details, please refer to the Announcement on the Capital Increase of Subsidiary Company Jianfeng Pharmaceutical to Shanghai Beika (P.2018 -025)
The (II) passed the Proposal on Subsidiary Company Shanghai Beika's Acquisition of Anhui Zhongwang.
Shanghai Beika Pharmaceutical Technology Co., Ltd., the company's controlling subsidiary, plans to invest 20.62 million yuan to acquire all 100 percent of Anhui Zhongwang Pharmaceutical Co., Ltd. After the acquisition, Anhui Zhongwang will become a wholly-owned subsidiary of Shanghai Beika.
After deliberation and voting, the board of directors passed the "Proposal on the Acquisition of Anhui Zhongwang by the Subsidiary Shanghai Beika".
Voting result: 9 votes in favor, 0 votes against, 0 abstentions.
For details, please refer to "Announcement on Subsidiary Shanghai Beika's Acquisition of Anhui Zhongwang" (P.2018 -023)
The (III) passed "Proposal on 2 billion Pieces of Solid Preparation Project of Jianfeng Pharmaceutical Jinxi Production Base"
After deliberation and voting, the board of directors passed "Proposal on 2 billion Pieces of Solid Preparation Project of Jianfeng Pharmaceutical Jinxi Production Base".
Voting Result: 9 votes in favor, 0 votes against and 0 abstentions. For details of
, please refer to the Announcement on the Annual Production of 2 billion Solid Preparations in Jinxi Production Base of Jianfeng Pharmaceutical (P.2018 -024)
This is to announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
August 3, 2008
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page